Market Overview

UPDATE: Barclays Begins Coverage on Cerner and Advisory Board

Related CERN
#PreMarket Primer: Thursday, September 4: Talk Of A Ceasefire In Ukraine
Top 4 NASDAQ Stocks In The Healthcare Information Services Industry With The Highest Profit Margin
This Is What a Growth Stock Looks Like (Fox Business)
Related ABCO
Zacks Rank #5 Additions For Thursday - Tale Of The Tape
Zacks Rank #5 Additions for Wednesday - Tale of the Tape

Barclays Wednesday reports includes a note from analyst Eric Percher for coverage initiation on Cerner (NASDAQ: CERN) and The Advisory Board Company (NASDAQ: ABCO) with an Overweight rating for each company. Price target of $79.

Percher notes, "Given our findings that the transition to value-based reimbursement and implementation of population health tools on a large scale will be at least a five- to seven-year journey, we favor companies that either provide services which will enable the journey itself or have demonstrated opportunities to drive growth outside of population health offerings. We believe no company is better positioned to advise hospital leadership than Advisory Board and Cerner's diversified growth strategy should drive double-digit growth even absent meaningful population health contributions."

ABCO closed Tuesday at $66.79 and opened Wednesday morning at $67. CERN closed previous session at $61.86 and opened at $61.94.

Latest Ratings for CERN

DateFirmActionFromTo
Sep 2014Topeka CapitalMaintainsBuy
Aug 2014Wells FargoUpgradesMarket PerformOutperform
Jul 2014Deutsche BankMaintainsBuy

View More Analyst Ratings for CERN
View the Latest Analyst Ratings

Posted-In: BarclaysPrice Target Initiation Analyst Ratings

 

Related Articles (ABCO + CERN)

Around the Web, We're Loving...

Partner Network

Get Benzinga's Newsletters